Andrew Wu

Andrew joined Frazier Healthcare Partners in July 2023 as a Senior Associate on the Growth Buyout team. He is involved with several of Frazier's portfolio companies, including Matrix Medical Network and United Derm Partners.

Prior to joining Frazier, Andrew was a Senior Manager at Zymergen, a publicly traded biotechnology company that has since been acquired by Ginkgo Bioworks. At Zymergen, Andrew worked across a variety of functions, including mergers and acquisitions, business development, and early-stage product development.

Prior to Zymergen, Andrew was an Investment Banking Associate Director at UBS, where he focused on mergers and acquisitions and capital markets activities for large-cap healthcare companies.

Andrew received his MBA from the Wharton School of the University of Pennsylvania and his BA in Economics from Yale University.